• Explore /
  • Poster
  • / Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.

Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.

Abstract Video & Slides Poster

Authors

Piotr Wysocki

Piotr Jan Wysocki

Jagiellonian University Medical College Hospital, Kraków, Poland

Piotr Jan Wysocki , Kyung Hae Jung , Do-Youn Oh , Deborah Blythe Doroshow , Elena Artamonova , Lemonitsa Mammatas , Po-Jung SU , Vladimir Moiseyenko , Konstantin Penkov , Daniil Stroyakovskiy , Jorge Bartolome , Salvatore Siena , Anitra Fielding , Lindsey Jung , Flavia Michelini , Soham D. Puvvada , Vicky Makker

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04482309

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4565)

DOI

10.1200/JCO.2024.42.16_suppl.4565

Abstract #

4565

Poster Bd #

260

Abstract Disclosures

Similar Posters

First Author: Do-Youn Oh

First Author: Nong Xu

First Author: Xinan Sheng

First Author: Wang Qu